Dermatology Times, June 2023 (Vol. 44. No. 06)

Any analysis of physician negligence must first begin with a legal description of the elements of negligence.

Learn more about the in-depth topics covered in the June 2023 issue of Dermatology Times®.

Findings from several large studies quantify the value that professional advisers bring to dermatology practices. Learn when to hone in on their expertise and when to take matters into your own hands.

Research and ongoing clinical trials are giving some hope to those with ichthyosis but for now most people manage their disease symptomatically.

In rare cases, chromhidrosis may be associated with underlying medical conditions, such as hyperthyroidism, dermatitis herpetiformis, and multiple myeloma.

With the social media boom, skin care advice is readily available. Unfortunately, some of the information on TikTok is harmful.

In recognition of World Vitiligo Day, the Dermatology Times team is spotlighting advances and educational opportunities for the condition.

In this month's Cosmetic Conundrums column, Zoe Diana Draelos, MD, discusses safe and effective skin care products for infants.

Ronda Farah, MD, and her colleagues reviewed how dermatology providers play an important role in transgender aesthetic care.

Four clinicians discuss the widening landscape of systemic therapies for patients with atopic dermatitis.

In one-third of cases of psoriasis, disease onset occurs in the first or second decade of life, although it may not be diagnosed until the patient has reached adulthood.

Zoe Diana Draelos, MD, editor in chief of Dermatology Times, reviews dermatology's role in pop culture and social media trends: "Popular skin culture has nothing on us but a new vocabulary."

The research delving into skin conditions affecting patients with skin of color, patients in the LGBTQIA+ community, and patients requiring multidisciplinary treatment continues to grow.

His keynote speech at ACMS focused on artificial intelligence for precision medicine and cancer diagnosis.

Katie Schlenker, DO, emphasizes the importance of empathy during tough conversations with skin cancer patients with few to no treatment options left.

The drug was both safe and effective in patients ages 6 months to 5 years.

Candrice Heath, MD, FAAP, FAAD, reviewed the important conversations dermatologists need to have to understand how racism affects SOC patients with atopic dermatitis at RAD 2023.

Brett King, MD, PhD, gave an in-depth overview of how JAK inhibitors earned a boxed warning and what it means for treating patients with atopic dermatitis at RAD 2023.

The PD-1 inhibitor pembrolizumab has proven its efficacy in a number of different cancers.

Transgender and cisgender patients presenting with acne face differences in acne treatment and prescribing patterns.

The autoinflammatory condition is associated with mutations in the NOD2 gene and usually affects children younger than 4 years.